- 2026-02-11
- PeerJ 14
- Yanwei Zhang
- Ming Liu
- Fengze Sun
- Bin Wang
- Yicheng Guo
- Yuchen Qian
- Jitao Wu
Study Design
- Type
- Meta-Analysis
- Sample size
- n = 611
- Population
- 611 patients from eight studies
- Methods
- Systematic search of PubMed, Embase, EBSCO, Cochrane Library, and Web of Science for RCTs on TXA treatment for bleeding during TURP; data analysis using Review Manager version 5.3
Background
Benign prostatic hyperplasia (BPH) is a common urinary system disease in elderly men, and transurethral resection of the prostate (TURP) is the gold standard for treating BPH. However, this surgery often leads to intraoperative and postoperative bleeding. Tranexamic acid (TXA) is an antifibrinolytic drug commonly used for hemostasis. This study aims to investigate the hemostatic effect of tranexamic acid in TURP surgery.Aim
Evaluate the efficacy of tranexamic acid in TURP surgery.Methods
We systematically searched the PubMed, Embase, EBSCO, Cochrane Library, and Web of Science databases for randomized controlled trials (RCTs) on TXA treatment for bleeding during transurethral resection of the prostate (TURP), published up to December 2025. Data analysis and management were performed using Review Manager version 5.3.Result
After applying the predefined inclusion and exclusion criteria, a total of eight studies involving 611 patients were included in our meta-analysis. The results of our analysis indicated that the TXA group significantly outperformed the control group in three outcomes: intraoperative blood loss (P = 0.04), postoperative 24-hour hemoglobin levels (P < 0.001), and postoperative 24-hour hemoglobin difference (P = 0.02). However, no significant differences were observed between the TXA and control groups regarding surgical time (P = 0.28) and length of hospital stay (P = 0.08).Conclusions
Compared to the control group, TXA significantly reduces intraoperative and postoperative bleeding in TURP surgery, making it valuable for anemic patients and in reducing surgical complications.